IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2

Aim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics.Materials and methods. 108 patients suffering from HP-associated gastric ulcer dis...

Full description

Bibliographic Details
Main Authors: T. A. Smirnova, O. V. Borovikov, E. I. Kleshenko, M. G. Kulagina, D. A. Kayumova, A. F. Komarov, E. V. Borovikova, E. P. Apalkova, L. M. Kravchenko
Format: Article
Language:Russian
Published: Ministry of Healthcare of the Russian Federation. “Kuban State Medical University” 2017-10-01
Series:Кубанский научный медицинский вестник
Subjects:
Online Access:https://ksma.elpub.ru/jour/article/view/834
_version_ 1797295463752269824
author T. A. Smirnova
O. V. Borovikov
E. I. Kleshenko
M. G. Kulagina
D. A. Kayumova
A. F. Komarov
E. V. Borovikova
E. P. Apalkova
L. M. Kravchenko
author_facet T. A. Smirnova
O. V. Borovikov
E. I. Kleshenko
M. G. Kulagina
D. A. Kayumova
A. F. Komarov
E. V. Borovikova
E. P. Apalkova
L. M. Kravchenko
author_sort T. A. Smirnova
collection DOAJ
description Aim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics.Materials and methods. 108 patients suffering from HP-associated gastric ulcer disease were randomly divided into two groups. The I group of patients was cured with standard three or four component methods of therapy included proton pomp inhibitors and two antibiotics (usually Klaritromycin and Amoxicillin). Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 – Roncoleukin into four – six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously. This procedure was performed three times with the interval of 72 hours.Results. One month after the end of treatment it was found that in the group treated with rIL-2 the HP eradication achieved in 95,4% in comparison to 81,5% in control patients. In Roncoleukin treated group ulcer epithelization period was 10,79±0,46 days and in traditionally treated group – 35,23±1,58 days. In third month of monitoring in gastric mucosae bioptates of basic group patients in 93,5% there were no morphological inflammatory signs and in 81,4% of patients intestinal metaplasia disappiered. Conclusion. The proposed method of complex treatment of gastric ulcer associated with Helicobacter pylori is clinically and pathogenetically justified.
first_indexed 2024-03-07T21:48:18Z
format Article
id doaj.art-3dc7e234a6c1454798fdad7b57481dbb
institution Directory Open Access Journal
issn 1608-6228
2541-9544
language Russian
last_indexed 2024-03-07T21:48:18Z
publishDate 2017-10-01
publisher Ministry of Healthcare of the Russian Federation. “Kuban State Medical University”
record_format Article
series Кубанский научный медицинский вестник
spelling doaj.art-3dc7e234a6c1454798fdad7b57481dbb2024-02-25T10:57:21ZrusMinistry of Healthcare of the Russian Federation. “Kuban State Medical University”Кубанский научный медицинский вестник1608-62282541-95442017-10-010412212710.25207/1608-6228-2017-24-4-122-127796IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2T. A. Smirnova0O. V. Borovikov1E. I. Kleshenko2M. G. Kulagina3D. A. Kayumova4A. F. Komarov5E. V. Borovikova6E. P. Apalkova7L. M. Kravchenko8Kuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityKuban State Medical UniversityAim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics.Materials and methods. 108 patients suffering from HP-associated gastric ulcer disease were randomly divided into two groups. The I group of patients was cured with standard three or four component methods of therapy included proton pomp inhibitors and two antibiotics (usually Klaritromycin and Amoxicillin). Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 – Roncoleukin into four – six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously. This procedure was performed three times with the interval of 72 hours.Results. One month after the end of treatment it was found that in the group treated with rIL-2 the HP eradication achieved in 95,4% in comparison to 81,5% in control patients. In Roncoleukin treated group ulcer epithelization period was 10,79±0,46 days and in traditionally treated group – 35,23±1,58 days. In third month of monitoring in gastric mucosae bioptates of basic group patients in 93,5% there were no morphological inflammatory signs and in 81,4% of patients intestinal metaplasia disappiered. Conclusion. The proposed method of complex treatment of gastric ulcer associated with Helicobacter pylori is clinically and pathogenetically justified.https://ksma.elpub.ru/jour/article/view/834gastric ulcer diseaseheliсobacter pyloria recombinant il-2
spellingShingle T. A. Smirnova
O. V. Borovikov
E. I. Kleshenko
M. G. Kulagina
D. A. Kayumova
A. F. Komarov
E. V. Borovikova
E. P. Apalkova
L. M. Kravchenko
IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
Кубанский научный медицинский вестник
gastric ulcer disease
heliсobacter pylori
a recombinant il-2
title IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
title_full IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
title_fullStr IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
title_full_unstemmed IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
title_short IMMUNOTHERAPY OF GASTRIC ULCER DISEASE, ASSOCIATED WITH HELIСOBACTER PYLORI USING RECOMBINANT IL-2
title_sort immunotherapy of gastric ulcer disease associated with heliсobacter pylori using recombinant il 2
topic gastric ulcer disease
heliсobacter pylori
a recombinant il-2
url https://ksma.elpub.ru/jour/article/view/834
work_keys_str_mv AT tasmirnova immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT ovborovikov immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT eikleshenko immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT mgkulagina immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT dakayumova immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT afkomarov immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT evborovikova immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT epapalkova immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2
AT lmkravchenko immunotherapyofgastriculcerdiseaseassociatedwithhelisobacterpyloriusingrecombinantil2